Singapore Health Services Pte Ltd (SingHealth) is Singapore’s largest public healthcare group and part of MOH Holdings. It oversees a network of acute and community hospitals, national specialty centres, and polyclinics, providing tertiary, specialist and primary care across the country. The group operates under the SingHealth Duke-NUS Academic Medical Centre, integrating clinical care with education and research.
SingHealth conducts and supports clinical and translational research in areas such as oncology, cardiovascular disease, neurosciences, ophthalmology, and women’s and children’s health. It facilitates industry collaborations, clinical trials, and technology development with academic partners, startups, and global biopharmaceutical companies, helping to advance diagnostics, therapeutics, and medical technologies. The organization also provides research infrastructure and governance, including ethics oversight and data frameworks, to enable rigorous, compliant studies relevant to biomedical and life science sectors.
BI 765423, targeting IL-11, enters Phase IIa trials for IPF, aiming to improve lung function. Pre-clinical studies show promise in halting fibrosis and restoring lung functionality.
